This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Axsome (AXSM) Q2 Earnings Top, AXS-05 Approval Likely Delayed
by Zacks Equity Research
Axsome Therapeutics (AXSM) reports narrower-than-expected Q2 loss. Yet, share price falls steeply after it notified of a potential delay in the approval of AXS-05 for major depressive disorder
Axsome Therapeutics (AXSM) Sees Hammer Chart Pattern: Time to Buy?
by Zacks Equity Research
Axsome Therapeutics (AXSM) has been struggling lately, but the selling pressure may be coming to an end soon.
Axsome (AXSM) Falls 10% After Losing Breakthrough Therapy Tag
by Zacks Equity Research
The FDA rescinds Breakthrough Therapy designation for Axsome's (AXSM) pipeline candidate, AXS-12. The company is developing AXS-12 for the potential treatment of cataplexy in narcolepsy patients.
Axsome (AXSM) Plans NDA Filing for Fibromyalgia Drug in 2022
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-14, which is being developed as a treatment of fibromyalgia. The company will file an NDA in the fourth quarter of 2022.
Why Is Axsome (AXSM) Up 14.7% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's (AXSM) Q1 Earnings Top, AXS-05 Launch in Focus
by Zacks Equity Research
Axsome (AXSM) reports narrower-than-expected loss for the first quarter of 2021. The company is gearing up to launch its first commercial product, AXS-05, following a potential approval.
Why Earnings Season Could Be Great for Axsome Therapeutics (AXSM)
by Zacks Equity Research
Axsome Therapeutics (AXSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Is a Beat in Store for Zoetis (ZTS) This Earnings Season?
by Zacks Equity Research
Zoetis (ZTS) will report earnings and revenues, and provide pipeline updates when it releases first-quarter 2021 results.
Is a Beat in Store for BioNTech (BNTX) This Earnings Season?
by Zacks Equity Research
On BioNTech's (BNTX) first-quarter earnings call, investors' focus will be on sales number of BNT162b2, its COVID-19 vaccine, which has been developed in partnership with Pfizer.
Novavax (NVAX) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Novavax's (NVAX) upcoming first-quarter earnings call, investor focus is expected to be on the company's progress with its COVID-19 vaccine candidate, NVX-CoV2373.
Editas (EDIT) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
On Editas' (EDIT) first-quarter earnings call, investor focus is expected to be on the company's progress with the development of its lead pipeline candidate - EDIT-101.
Alexion (ALXN) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Alexion (ALXN) is set to provide updates on revenues and earnings when it releases first-quarter 2021 results on May 3.
Is a Beat in Store for CRISPR (CRSP) This Earnings Season?
by Zacks Equity Research
On CRISPR Therapeutics' (CRSP) first-quarter earnings call, investor focus will be on updates of the company's progress with the development of its lead gene-editing candidate, CTX001.
Alzheimer's Disease: 5 Stocks on Biotech Radars
by Kevin Cook
While Biogen rides a big-cap rollercoaster, a few small players are creating better trading opps.
Why Is Axsome (AXSM) Down 19.9% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's (AXSM) Q4 Earnings Miss Estimates, Pipeline in Focus
by Zacks Equity Research
Axsome (AXSM) reports wider-than-expected loss in the fourth quarter of 2020. The company files an NDA for AXS-05 to treat major depressive disorder.
Biotech Bonanza: COVID Launches Science at Warp Speed
by Kevin Cook
From vaccines to diagnostics, the opportunities in biotechnology are rich for those who do their homework.
Implied Volatility Surging for Axsome Therapeutics (AXSM) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Axsome Therapeutics (AXSM) stock based on the movements in the options market lately.
Axsome's (AXSM) Migraine Drug Shows Long-Term Safety in Study
by Zacks Equity Research
Axsome (AXSM) posts favorable data from the long-term phase III study evaluating AXS-07 for acute treatment of migraine. The company also begins a second phase III study on AXS-05 for AD agitation.
Why Is Axsome (AXSM) Up 15.2% Since Last Earnings Report?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's (AXSM) Q3 Earnings In Line, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) earnings meet estimates in the third quarter. The company stretches the timeline for the NDA filing for AXS-05 and AXS-07. Shares fall.
Axsome Expedites Development Plan for Narcolepsy Candidate
by Zacks Equity Research
Axsome (AXSM) accelerates the development plan for AXS-12 to treat narcolepsy after a Breakthrough Therapy meeting with the FDA authorities. Stock dips.
Axsome (AXSM) Down 10.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's NDA Filing for Migraine Candidate in Q4 on Track
by Zacks Equity Research
Axsome (AXSM) concludes a favorable pre-NDA meeting with the FDA for AXS-07, which is developed as an acute treatment of migraine. The company is on course to file the NDA in Q4.
Axsome's (AXSM) Earnings Beat in Q2, Pipeline Progresses
by Zacks Equity Research
Axsome (AXSM) incurs a narrower loss in the second quarter of 2020. The company remains on track to submit the NDA for AXS-05 and AXS-07.